Centre for Advanced Research in Bacteriophage and Infectious Diseases (CARBID)
Centre for Advanced Research in Bacteriophage and Infectious Diseases (CARBID)
To become a worldwide hub for cutting-edge research in bacteriophage therapy and infectious diseases, and to offer solutions for acute and chronic bacterial diseases.
- To develop and supply bacteriophages for the treatment of skin and musculoskeletal infections.
- To provide bacteriophages targeting multidrug-resistant (MDR), extensively drug-resistant (XDR), and pan-drug-resistant (PDR) bacterial pathogens.
- To promote awareness and understanding of phage therapy among clinicians, pharmacists, researchers, and the general public.
- To supply and support the application of bacteriophages across diverse sectors, including medical, agricultural, environmental, and aquaculture fields.
About CARBID
The Centre for Advanced Research in Bacteriophage and Infectious Diseases (CARBID) was established at Vellore Institute of Technology by Dr. N. Ramesh under the prestigious extramural “Centre for Advanced Research” program funded by the Indian Council of Medical Research (ICMR), Government of India, New Delhi. Recognizing his expertise in bacteriophage research, Dr. Ramesh Nachimuthu was appointed as an expert committee member by the Director General of the Indian Council of Medical Research to guide bacteriophage research initiatives in India.
CARBID is dedicated to advancing cutting-edge research in the isolation, characterization, and therapeutic application of bacteriophages to combat life-threatening bacterial infections, particularly in the context of rising antimicrobial resistance. The Centre actively undertakes multidisciplinary research and development (R&D) projects, translational research, and consultancy services in infectious disease management. With a strong network of national and international collaborations, CARBID works closely with leading scientists, clinicians, and research institutions to accelerate innovation and promote the development of bacteriophage-based therapeutic solutions.
Principal Investigator
Dr. N. Ramesh
-
Established CARBID under the ICMR-funded extramural “Centre for Advanced Research” program.
-
Expert Committee Member for bacteriophage research (identified by Director General, ICMR)
Core Research Domains
- Therapeutic Bacteriophages & Phage Cocktails
- AMR Pathogens (including ESKAPE organisms)
- Biofilm Biology & Phage-Biofilm Interactions
- Phage–Antibiotic Combination Strategies
- Translational Phage R&D and Clinical-Pathogen Targeting
Sponsored Research Projects
1. Bacteriophage Cocktails for Acute Respiratory Infections caused by MDR ESKAPE Pathogens, Agency: DHR–ICMR, Govt. of India, Duration: 2024–2027, PI: Dr. N. Ramesh, Grant: ₹37,83,990
2. Siderophore–Macrolide Antibiotic Conjugates to Combat MDR Gram-Negative Infections, Agency: ICMR, Govt. of India, Duration: 2024–2027, PI: Dr. N. Ramesh, Grant: ₹52,68,000
3. Centre for Advanced Research (CAR): Generation of bacteriophages for combating bacterial infections of the skin and musculoskeletal system, Agency: ICMR, Govt. of India, Duration: 2024–2029, PI: Dr. N. Ramesh, Co-PI: Dr. A. Sivakumar, Total Grant: ₹9,84,28,958, VIT Share: ₹4,81,74,346/-
4. Development of Pitcher plant -inspired Liquid-Infused and Multi Modal Bio selective Implant Coating for Combating Implant-Associated Infections and Bone Losses (IRPIG2025-01-00837. Agency ICMR, Govt. of India, Duration: 2026–2028, PI: Dr. Debasish Mishra, Co-PI: Dr. N. Ramesh, Grant: 3,00,01,00,0/-
1. Transcriptional Repression of dcw Operon in Mycobacteria: Transcriptomic & Proteomic Analysis Agency: DST–SERB, Duration: 2018–2020, Mentor: Dr. N. Ramesh, Grant: ₹22,64,349
2. Efficient Bacteriophage against NDM-1 producing E. coli and Klebsiella pneumoniae Agency: DST–SERB, Duration: 2013–2016, PI: Dr. N. Ramesh, Grant: ₹29,04,193
Industry Consultancy & Services
CARBID provides validated testing and R&D support for antimicrobial and anti-biofilm solutions.
- MIC testing against MRSA/MSSA clinical isolates, Vyome Biosciences, New Delhi, ₹6,25,000
- MIC testing against MDR clinical isolates (ESKAPE and other priority pathogens), Vyome Therapeutics, New Delhi ,₹6,25,000
- Compound screening and validation against E. coli and Staphylococcus, Liquid Cubes Innocommerce, Bangalore, ₹1,50,000
Patent Granted
Inventors: Dr. N. Ramesh, Mr. Prasanth Manohar
Application No.: TEMP/E-1/37319/2018-CHE
Publications & Research Output
CARBID’s work is published in leading international journals covering bacteriophage therapy, AMR, infectious diseases, and biofilms.
- Recent Publications (2025)
- Selected Publications (2024)
- Juliet R., Nachimuthu R. (2025). Frontiers in Cellular and Infection Microbiology (IF 4.8)
- Juliet R., Nachimuthu R. (2025). BMC Microbiology (IF 4.2)
- Ali S. et al. (2025). PHAGE (IF 3.6)
- Juliet R. et al. (2024). Frontiers in Microbiology (IF 5.6)
- Manohar P. et al. (2024). Scientific Reports (IF 4.6)
- Loganathan A. et al. (2024). Frontiers in Pharmacology (IF 5.0)
- Manohar P. et al. (2024). Frontiers in Microbiology (IF 5.2)
Collaborations
CARBID maintains strong national and international collaborations with leading scientists, clinicians, and research institutions to accelerate bacteriophage-based innovation and translational outcomes.
Opportunities
- Research collaboration proposals (national/international)
- Industry partnerships and consultancy
- Student internships and project mentorship (UG/PG/PhD)
- Joint publications and grant development
Contact
Dr. N. Ramesh
Associate Professor
CARBID – Centre for Advanced Research in Bacteriophage and Infectious Diseases
SBST, Vellore Institute of Technology (VIT), Vellore, Tamil Nadu, India.
- 9842660673
- ramesh.n@vit.ac.in
- PRP A block (G51-54)

